Neurocrine Biosciences | NBIX - Current Liabilities



Neurocrine Biosciences reported $546.3M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
AbbVie USD 36.4B 2.35B Mar/2025
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
ALKERMES USD 505.96M 62.23M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Amgen USD 20.48B 2.53B Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
Dynavax Technologies USD 118.23M 49.85M Jun/2025
Exelixis USD 336.11M 62.99M Jul/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Halozyme Therapeutics USD 134.28M 16.1M Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
Ionis Pharmaceuticals USD 897.24M 646.94M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Prothena USD 67.81M 19.31M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Repligen USD 152M 25.21M Mar/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Teva Pharmaceutical Industries USD 11.86B 704M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025